|
|
||||||||



*
Mouse Immunogenetics, U462, Institut National de la Santé et de la Recherche Médicale, Institute of Hematology, Saint-Louis Hospital, Paris, France; and
Institut für Anthropologie und Humangenetik, Ludwig-Maximilians-Universität, Munich, Germany
We have introduced the gene (E*01033) encoding the heavy chain of the human nonclassical MHC class I Ag, HLA-E, into the mouse genome. Two founder mice carry a 21-kb fragment, the others bear an 8-kb fragment. Each of the founder mice was mated to mice of an already established C57BL/10 transgenic line expressing human ß2-microglobulin (ß2m). Cell surface HLA-E was detected on lymph node cells by flow cytometry only in the presence of endogenous human ß2m. However, HLA-E-reactive mouse CTL (H-2-unrestricted) lysed efficiently the target cells originating from HLA-E transgenic mice without human ß2m, showing that the HLA-E protein can be transported to the cell surface in the absence of human ß2m, presumably by association with murine ß2m. Rejection of skin grafts from HLA-E transgenic mice demonstrates that HLA-E behaves as a transplantation Ag in mice. HLA-E transgenic spleen cells are effective in stimulating an allogeneic CTL response in normal and human classical class I (HLA-B27) transgenic mice. Furthermore, results from split-well analysis indicate that the majority of the primary in vivo-induced CTL recognizes HLA-E as an intact molecule (H-2-unrestricted recognition) and not as an HLA-E-derived peptide presented by a mouse MHC molecule, although a small fraction (ranging from 4 to 21%) of the primary in vivo-induced CTL is able to recognize HLA-E in an H-2-restricted manner. Based on these observations, we conclude that HLA-E exhibits alloantigenic properties that are indistinguishable from classical HLA class I molecules when expressed in transgenic mice.
This article has been cited by other articles:
![]() |
T. Tilburgs, D. L. Roelen, B. J. van der Mast, G. M. de Groot-Swings, C. Kleijburg, S. A. Scherjon, and F. H. Claas Evidence for a Selective Migration of Fetus-Specific CD4+CD25bright Regulatory T Cells from the Peripheral Blood to the Decidua in Human Pregnancy J. Immunol., April 15, 2008; 180(8): 5737 - 5745. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Miller, D. A. Weber, C. Ibegbu, J. Pohl, J. D. Altman, and P. E. Jensen Analysis of HLA-E Peptide-Binding Specificity and Contact Residues in Bound Peptide Required for Recognition by CD94/NKG2 J. Immunol., August 1, 2003; 171(3): 1369 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Romagnani, G. Pietra, M. Falco, E. Millo, P. Mazzarino, R. Biassoni, A. Moretta, L. Moretta, and M. C. Mingari Identification of HLA-E-specific alloreactive T lymphocytes: A cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells PNAS, August 20, 2002; 99(17): 11328 - 11333. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, I. Goldstein, E. Glickman-Nir, H. Jiang, and L. Chess Induction of TCR V{beta}-Specific CD8+ CTLs by TCR V{beta}-Derived Peptides Bound to HLA-E J. Immunol., October 1, 2001; 167(7): 3800 - 3808. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Horuzsko, F. Lenfant, D. H. Munn, and A. L. Mellor Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice Int. Immunol., March 1, 2001; 13(3): 385 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Szpak, J.-C. Vieville, T. Tabary, M.-C. Naud, M. Chopin, C. Edelson, J. H. M. Cohen, J. Dausset, Y. de Kozak, and M. Pla Spontaneous retinopathy in HLA-A29 transgenic mice PNAS, February 8, 2001; (2001) 51595998. [Abstract] [Full Text] |
||||
![]() |
Y. Szpak, J.-C. Vieville, T. Tabary, M.-C. Naud, M. Chopin, C. Edelson, J. H. M. Cohen, J. Dausset, Y. de Kozak, and M. Pla Spontaneous retinopathy in HLA-A29 transgenic mice PNAS, February 27, 2001; 98(5): 2572 - 2576. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |